Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stockDiscovery themes featuring this stockDiscover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Shalby Ltd (SHALBY) is currently trading at 147.85 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Shalby Limited is an Ahmedabad‑headquartered integrated healthcare group operating 15 hospitals with 2,300+ beds across India and a growing implant MedTech vertical, combining multi‑specialty hospital services and an in‑house implant manufacturing and distribution platform (SAT, SMT, SGT). The company also operates international OPDs and owns an implant facility in California. Q3 FY26 consolidated revenue was INR 2,794 million (down 0.6% YoY) with consolidated EBITDA of INR 375 million and consolidated net debt of INR 4,086 million; standalone hospital EBITDA and PBT declined materially QoQ and YoY, highlighting near‑term margin pressure at hospital operations despite steady ARPOB and improving PAT. Annualized ROCE stands at 6.7% consolidated. Shalby MedTech shows a clear turnaround: Q3 MedTech consolidated revenue grew 29% YoY to INR 303.8 million with EBITDA turning positive versus a prior loss, and 9M FY26 MedTech revenue up 47% YoY to INR 949 million, reflecting stronger India execution, improved supply chain and product launches across markets including North America, Japan and Southeast Asia. Clinical and technology investments are accelerating clinical mix and premium services: robotic orthopedic and multi‑specialty deployments, radiotherapy/PET‑CT installations, launch of liver, kidney and bone marrow transplant programs and national recognition on ICU standards. Management emphasizes leveraging these capabilities to raise ARPOB, occupancy and tertiary high‑margin volumes. Capital strategy is pragmatic: limited large new capex in next 12 months, focused investments (bunkers, robots, diagnostics), selective inorganic consolidation and intent to reduce net debt as MedTech and hospital cash flows improve, while targeting a meaningful ROCE uplift driven by operational leverage.
Over the past 52 weeks, Shalby Ltd has traded between a low of ₹144.55 and a high of ₹274.50. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Shalby Ltd has a market capitalization of approximately 1,590.98. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Shalby Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 387.89 and operates in the Healthcare sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,590.98 Cr, Shalby Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Shalby Ltd operates in the Healthcare sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Shalby Ltd is 387.89. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
4462.00 | 2,171 Cr | 30.65 | 6.90 | 0.13 | 20.02 | 14.77 | 9.58 | |
147.40 | 1,591 Cr | 387.89 | 1.59 | 0.00 | 0.45 | 6.06 | 0.23 | |
81.84 | 1,335 Cr | 36.70 | 7.33 | 0.00 | 16.69 | 19.54 | 12.23 | |
121.45 | 1,060 Cr | 23.27 | 5.35 | 2.71 | 26.36 | 23.95 | 0.00 | |
109.10 | 859 Cr | 58.97 | 3.10 | 0.00 | 36.29 | 39.11 | 0.00 | |
80.36 | 588 Cr | 25.76 | 4.31 | 0.00 | 39.91 | 39.92 | — | |
321.55 | 498 Cr | 32.71 | 4.75 | 0.00 | 19.24 | 34.76 | 21.01 |
Bearish
3
Neutral
3
Bullish
8
Bearish
35
Neutral
3
Bullish
8
Bearish
32
Neutral
0
Bullish
0
Accreditation Announcement
PK Healthcare Pvt. Ltd. (Shalby International Hospitals), a Gurugram subsidiary of Shalby Limited, has been awarded NABH accreditation under the 6th Edition, valid until 2030, recognising compliance with national patient-safety and quality standards.
Accreditation Announcement
PK Healthcare Pvt. Ltd. (Shalby International Hospitals), a subsidiary of Shalby Limited, has been granted NABH 6th Edition accreditation (announced March 3, 2026), valid until 2030, for enhanced patient safety and quality.
Rights Issue Allotment
PK Healthcare credited 5,96,01,950 equity shares to Shalby on Feb 28, 2026 at Rs.10/share (Rs.59.60 crore) under a rights issue, raising Shalby’s stake in PKHPL from 87.26% to 91.13%; proceeds used for debt repayment and working capital.
Shareholding Change
Shalby Ltd received 5,96,01,950 equity shares from subsidiary PK Healthcare via a rights issue at Rs.10/share (₹59.60 crore), raising its stake from 87.26% to 91.13%; proceeds used for debt repayment, working capital and general purposes.
Shalby Limited is an Ahmedabad‑headquartered integrated healthcare group operating 15 hospitals with 2,300+ beds across India and a growing implant MedTech vertical, combining multi‑specialty hospital services and an in‑house implant manufacturing and distribution platform (SAT, SMT, SGT). The company also operates international OPDs and owns an implant facility in California.
Q3 FY26 consolidated revenue was INR 2,794 million (down 0.6% YoY) with consolidated EBITDA of INR 375 million and consolidated net debt of INR 4,086 million; standalone hospital EBITDA and PBT declined materially QoQ and YoY, highlighting near‑term margin pressure at hospital operations despite steady ARPOB and improving PAT. Annualized ROCE stands at 6.7% consolidated.
Shalby MedTech shows a clear turnaround: Q3 MedTech consolidated revenue grew 29% YoY to INR 303.8 million with EBITDA turning positive versus a prior loss, and 9M FY26 MedTech revenue up 47% YoY to INR 949 million, reflecting stronger India execution, improved supply chain and product launches across markets including North America, Japan and Southeast Asia.
Clinical and technology investments are accelerating clinical mix and premium services: robotic orthopedic and multi‑specialty deployments, radiotherapy/PET‑CT installations, launch of liver, kidney and bone marrow transplant programs and national recognition on ICU standards. Management emphasizes leveraging these capabilities to raise ARPOB, occupancy and tertiary high‑margin volumes.
Capital strategy is pragmatic: limited large new capex in next 12 months, focused investments (bunkers, robots, diagnostics), selective inorganic consolidation and intent to reduce net debt as MedTech and hospital cash flows improve, while targeting a meaningful ROCE uplift driven by operational leverage.
Healthcare
Hospitals / Medical Services
1,591 Cr
Moderate Risk
387.9
60.2
1.9
1.6
274.50
145.40
Sales CAGR
Profit CAGR
ROE
ROCE
